Uncategorized Archives - Page 135 of 137

ThursdayJun 04, 2020 11:45 am

Predictive Oncology Inc. (NASDAQ: POAI) CEO Discusses Acquisitions, Exclusive Database of Historical Tumor Data in Recent Interview

POAI boasts unique historical database documenting actual drug responses of tumors – the largest in the world with over 150,000 tumors across 137 types Drug discovery funding for subsidiary Helomics planned through relationships with large pharmaceutical companies Company planning to acquire two new biological firms in the precision medicine space Predictive Oncology Inc. (NASDAQ: POAI) is a knowledge-driven medicine company focused on applying data and artificial intelligence (AI) to cancer personalized medicine and drug discovery. In a recent interview (http://nnw.fm/o7Ysq), POAI director and CEO Dr. Carl Schwartz discussed the acquisition of two biological firms, along with details about the company’s…

TuesdayJun 02, 2020 12:34 pm

Predictive Oncology Inc.’s (NASDAQ: POAI) Subsidiary a ‘Major Asset’ in Growing Precision Medicine Space

POAI addresses pressing need for a multi-omic approach in field of precision medicine Global precision medicine market is expected to reach total market value of approximately $84 billion by 2026 Predictive Oncology’s ‘claim to fame’ is its inventory of over 150,000 tumors covering over 137 types of cancer, with over 30,000 related to ovarian cancer In the burgeoning world of precision medicine, Predictive Oncology Inc. (NASDAQ: POAI) appears ideally positioned to address one of the most pressing problems in the industry: the need for a multi-omic approach to precision therapy that may offer markedly improved patient outcomes over just genomics alone.…

FridayMay 22, 2020 12:06 pm

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Leverages Cutting-Edge Tech and Datasets to Improve Cancer Outcomes

POAI subsidiary Helomics helps oncologists individualize cancer treatment using patient-derived tumor models to improve outcomes Helomics’ tumor genomic and drug response database is one of the largest in the world with over 150,000 tumors across 137 cancer types Expected CAGR of 10.3% from 2018-2024 for oncology segment of precision medicine industry The relationship between a patient and their cancer is personal: it’s specific, and it necessitates personalized treatment to be defeated effectively. Unfortunately, oncologists’ ability to personalize treatment for patients has largely been anything but, often resembling a trial-and-error method. This is largely because we have few targeted treatments or…

TuesdayMay 12, 2020 10:30 am

Predictive Oncology Inc. (NASDAQ: POAI) CEO Enters into Debt-to-Equity Agreement, Touts Company’s Major Asset

POAI CEO exchanges $2.1 million promissory note for newly issued stock shares Strategic agreement enables company to strengthen balance sheet, simplify capital structure in plan to commercialize highly valuable database Because of its unique patient inventory, Helomics is only company with ability to profile tumors In a significant move indicating strong confidence in the company’s future, Predictive Oncology Inc. (NASDAQ: POAI) CEO Dr. Carl Schwartz has entered into an agreement exchanging a $2.1 million promissory note for equity in the company, which has established itself as a leader in the cancer precision-medicine field. In addition, during a recent interview, Schwartz…

FridayMay 01, 2020 11:29 am

Predictive Oncology Inc. (NASDAQ: POAI) Streamlines Capital, Simplifies Balance Sheet through Debt Exchange

POAI CEO exchanges $2.1 promissory note for shares of common stock Agreement enables Predictive Oncology to strengthen balance sheet, simplify capital structure at critical juncture in quest to commercialize highly valuable database POAI cancels outstanding debt of $2,115,000 in aggregate principal amount of 12% promissory note Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery, has entered into an agreement with its CEO to exchange a $2.1 million promissory note for newly issued equity (http://nnw.fm/Y1UeQ). The strategic move demonstrates the confidence CEO Dr. Carl Schwartz has in the growing company. “This agreement…

TuesdayApr 21, 2020 12:59 pm

Predictive Oncology Inc. (NASDAQ: POAI) Releases FY Financials, Notes Key Partnerships, CancerQuest 2020 Milestones Achieved

Q4 highlights include $15 million equity line, CancerQuest 2020 initiative POAI revenues for FY 2019 total $1.4 million, primarily driven through sale of proprietary STREAMWAY units Predictive Oncology will continue to be pioneer in fields of biomarker discovery, precision therapies Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying its cutting-edge technology to cancer research, released its financial report for fiscal year 2019, ending December 31, 2019. The report also identified fourth-quarter highlights for the company (http://nnw.fm/5uhu6). Noting that 2019 “was not without its challenges for the entire healthcare technology industry,” POAI CFO Bob Myers observed that Predictive Oncology “continued…

ThursdayApr 09, 2020 12:29 pm

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Continues Progress Toward AI-Driven Predictive Model of Ovarian Cancer

POAI’s Helomics division progresses toward critical milestone in CancerQuest2020 initiative Predictive models immensely valuable to pharmaceutical industry, improving drug evaluation without incurring high laboratory costs POAI is bringing precision medicine to the treatment of cancer for patients of today and tomorrow Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to personalized medicine and drug discovery, today announced continued progress by its Helomics subsidiary toward the goal of developing an AI-driven predictive model of ovarian cancer. This achievement will be a key milestone for the company’s CancerQuest2020 initiative (http://nnw.fm/W2TJb). CancerQuest2020 is focused on building an…

ThursdayMar 26, 2020 12:42 pm

Predictive Oncology Inc. (NASDAQ: POAI) Enters into Securities Purchase Agreement to Raise $3.5 Million

POAI announces securities purchase agreement with accredited investors to purchase shares of common stock Company to use net proceeds from purchase agreement for general corporate purposes Agreement expected to raise $3.5 million through issuance of up to 1,650,165 shares of common stock or common stock equivalents Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, entered into a securities purchase agreement with certain accredited investors to purchase shares of common stock; the company plans to use the net proceeds from the purchase agreement for general corporate purposes. POAI, a company that focuses on providing predictive models of tumor drug…

ThursdayMar 19, 2020 12:25 pm

AI Accelerates Vaccine Development; Predictive Oncology Inc. (NASDAQ: POAI) Launches AI Platform to Battle Coronaviruses, Acute Respiratory Syndromes

Artificial Intelligence at the forefront of scientific discovery, proving importance in complex diseases Predictive Oncology launches new AI platform in fight against new pathogens Artificial intelligence likely to help find COVID-19 vaccines and therapeutics With the global onslaught of COVID-19, scientists are turning to the speed and power of artificial intelligence to find solutions. The complexity of this lethal contagion demands a rapid response, and only advanced computer systems can parse through massive amounts of data swiftly enough to help stem the pandemic. Artificial intelligence can sort and sift data quickly, spot patterns and make predictions – which can then…

TuesdayMar 17, 2020 12:10 pm

Predictive Oncology Inc.’s (NASDAQ: POAI) AI Solutions to Combat Cancer, Similar Technological Solutions Called Upon to Fight COVID-19

Artificial intelligence (AI) at forefront of scientific discovery, proving importance in fighting complex diseases Science turns to AI as effective tool to help find COVID-19 vaccines and therapeutics Predictive Oncology harnesses power of AI to improve cancer patient outcomes With the global onslaught of COVID-19, scientists are harnessing the speed and power of artificial intelligence (AI) to find solutions. The complexity of this lethal contagion demands a rapid yet comprehensive response, and only advanced computer systems can parse through mountains of data sets swiftly enough to stem the pandemic. AI’s ability to sort and sift data quickly, spot patterns and…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Predictive Oncology Inc. (NASDAQ: POAI) CEO Discusses Acquisitions, Exclusive Database of Historical Tumor Data in Recent Interview

Predictive Oncology Inc.’s (NASDAQ: POAI) Subsidiary a ‘Major Asset’ in Growing Precision Medicine Space

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Leverages Cutting-Edge Tech and Datasets to Improve Cancer Outcomes

Predictive Oncology Inc. (NASDAQ: POAI) CEO Enters into Debt-to-Equity Agreement, Touts Company’s Major Asset

Predictive Oncology Inc. (NASDAQ: POAI) Streamlines Capital, Simplifies Balance Sheet through Debt Exchange

Predictive Oncology Inc. (NASDAQ: POAI) Releases FY Financials, Notes Key Partnerships, CancerQuest 2020 Milestones Achieved

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Continues Progress Toward AI-Driven Predictive Model of Ovarian Cancer

Predictive Oncology Inc. (NASDAQ: POAI) Enters into Securities Purchase Agreement to Raise $3.5 Million

AI Accelerates Vaccine Development; Predictive Oncology Inc. (NASDAQ: POAI) Launches AI Platform to Battle Coronaviruses, Acute Respiratory Syndromes

Predictive Oncology Inc.’s (NASDAQ: POAI) AI Solutions to Combat Cancer, Similar Technological Solutions Called Upon to Fight COVID-19

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search